GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial

October 13, 2022

https://www.globenewswire.com/news-release/2022/10/13/2533896/8060/en/GSK-s-older-adult-RSV-vaccine-candidate-containing-Agenus-QS-21-STIMULON-shows-94-1-reduction-in-severe-RSV-disease-and-overall-vaccine-efficacy-of-82-6-in-pivotal-trial.html

LEXINGTON, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of therapies and adjuvants designed to activate the immune response to cancer and infections, today shared that GSK has disclosed positive pivotal phase III trial results for its respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above and plans to present full data at ID Week on October 20th. The vaccine candidate was highly efficacious, demonstrating overall vaccine efficacy of 82.6% (96.95% CI, 57.9–94.1) against RSV lower respiratory tract disease (RSV-LRTD), meeting the trial’s primary endpoint.

Read more at globenewswire.com

Related news for (AGEN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.